CD99 and neoplasm: Accordingly, anti-CD99 antibodies exert additive/synergistic effects when combined with conventional agents, such as doxorubicin or vincristine (Guerzoni et al. 2015; Scotlandi et al. 2006) and are effective even against chemoresistant tumor cells (Manara et al. 2016).